Introduction
============

Uterine fibroids (UFs) are benign tumors that affect 20%--40% of women of reproductive age, of which \~10%--20% are symptomatic.[@b1-ceor-9-669] In clinical practice, detection of UF with ultrasound is often sufficient when the myomas are not numerous.[@b2-ceor-9-669] Depending on their number, volume, and location in the uterus,[@b3-ceor-9-669] UF can cause symptoms such as abnormal uterine bleeding, pelvic pressure and pain, and fertility disorders.[@b4-ceor-9-669] Insufficient treatment can result in lowered quality of life (QOL) and increased economic burden borne by patients and society.[@b5-ceor-9-669]

The main goal of UF treatment is symptom reduction, and the choice of approach is usually determined by a number of medical and social factors such as age, childbearing aspirations, extent and severity of symptoms, fibroid characteristics (size, number, and location), associated medical conditions, possibility of malignancy, proximity to menopause, and desire for uterine preservation.[@b1-ceor-9-669],[@b6-ceor-9-669],[@b7-ceor-9-669] When surgery is contraindicated or patients wish to avoid it, less-invasive pharmaceutical treatment options such as antifibrinolytics, oral contraceptives, and levonorgestrel intrauterine system are all potential treatment options in contemporary clinical practice. However, these alternatives do not treat the underlying UF, are often insufficient for patients with moderate to severe symptoms, and may lead to suboptimal treatment of UF or situations where patients are not treated at all. When standard pharmaceutical therapies do not sufficiently control symptoms of UF and surgery is contraindicated or undesirable, non-steroidal anti-inflammatory drugs (NSAIDs) and iron supplements may be given alone. In some cases, if symptoms become unbearable, the patient may undergo surgery despite a preference to avoid it. For these patients, best supportive care (BSC) consists of treatment with NSAIDs and iron supplements followed by surgery as needed. In reality, some patients may continue to receive standard pharmaceutical treatments in addition to NSAIDs and iron despite a lack of satisfactory effect. According to the definition of the patient population, these standard pharmaceuticals do not impact efficacy in a meaningful way and thus were not considered in this research.

Ulipristal acetate, a selective progesterone receptor modulator, is a treatment option for women with moderate to severe symptoms of UF, which can be given on a repeated intermittent basis. Although intermittent ulipristal acetate 5 mg (UPA) has been shown to effectively control bleeding and pain, reduce fibroid volume, and improve QOL in patients with symptomatic fibroids in a clinical trial context,[@b8-ceor-9-669] the cost-effectiveness of such strategy has not been fully assessed. Only one previously published study has analyzed the cost-effectiveness of repeated intermittent UPA treatment in an Italian setting, where repeated intermittent use (4--10 courses) was found to be cost-effective compared to the pre-surgical use of UPA for two courses.[@b9-ceor-9-669]

This study aims to extend previous research by providing a cost-effectiveness analysis of the repeated intermittent UPA indication in the long term for women failing on standard pharmaceutical treatments with a wish to avoid surgery.

Methods
=======

Analytical approach
-------------------

The decision problem considered in this evaluation is whether it is cost-effective to treat patients with UPA followed by surgery as needed, instead of BSC, in England. A decision-analytic model was designed to estimate long-term costs and health outcomes, measured by quality-adjusted life years (QALYs), associated with both treatment strategies using data from the published clinical trials of UPA. Clinical trial data were synthesized with cost and QOL information from other sources to provide inputs to the model. The primary outcome of the analysis is the incremental cost-effectiveness ratio (ICER), calculated as the per-patient mean difference in cost to the health care sector divided by the per-patient mean difference in QALYs gained. Cost-effectiveness was assessed by comparing the ICER to the cost-effectiveness threshold range used by NICE in England, which is currently stated to be between 20,000 and 30,000 GBP.[@b10-ceor-9-669]

Patients and interventions
--------------------------

The patient population of interest in this evaluation includes women eligible for treatment with UPA who are contraindicated for, or wish to avoid, surgery and do not experience sufficient response to standard pharmaceutical treatments.

With the UPA strategy, 5 mg is taken orally once daily as a tablet and can be given on a repeated intermittent basis. Patients eligible for UPA are indicated to receive 3 months of UPA followed by a break of at least 2 months. Although presently unstudied, in theory, women exhibiting symptom control beyond 2 months may extend the break for as long as they are asymptomatic. Patients in the UPA strategy may withdraw to either BSC or directly to surgery if treatment does not sufficiently resolve UF symptoms.

With the BSC strategy, patients begin by receiving NSAIDs and iron supplements. In reality, some patients may also receive standard pharmaceutical treatments, despite a lack of satisfactory effect. It was assumed that these treatments do not have an impact on efficacy and thus were not explicitly modeled. As in the UPA arm, patients who experience unbearable symptoms may elect to undergo surgery, despite their wish to avoid it.

Decision-analytic model
-----------------------

A decision-analytic model was designed to estimate clinical pathways in both treatment arms[@b11-ceor-9-669] by incorporating levels of pain/discomfort and bleeding, found in the published UPA clinical trials. In each monthly cycle, the number of patients remaining on treatment as well as the level of bleeding and pain is updated in the model. The model development followed the guidelines set by NICE.[@b12-ceor-9-669] In the base-case analysis, the National Health Service (NHS) payer perspective in an English setting was used, and discount rates were applied at a rate of 3.5% per annum for both costs and QALYs.

Patients enter the model at 41.5 years of age, the average age in the PEARL IV[@b13-ceor-9-669] trial. Treatment ends at the average age of menopause (51.4 years),[@b14-ceor-9-669] where no significant differences between the two treatments are assumed due to the regression of symptoms of UF.[@b15-ceor-9-669]

Patients begin the model on treatment with either UPA or iron+NSAID and can transition according to the specification in [Figure 1](#f1-ceor-9-669){ref-type="fig"}. Patients could withdraw from UPA to treatment with iron+NSAID and remain symptomatic, receive surgery, or die. Patients who receive surgery face a procedural risk of dying (red arrow in [Figure 1](#f1-ceor-9-669){ref-type="fig"}). This risk was 0.038% and 0.02% for hysterectomy and uterine artery embolization (UAE), respectively. No increased mortality risk was applied to patients receiving myomectomies.[@b16-ceor-9-669] Patients receiving a non-hysterectomy surgery are subsequently at risk of resurgery. Any patient who did not die during the month of surgery is subsequently assumed to have QOL equivalent to a member of the general population. Patients are also at risk of dying from any cause at all times, represented by orange arrows.

The possibility of withdrawing to surgery with both treatment strategies reflects the fact that surgery may become an acceptable option, despite an initial wish to avoid a procedure, when symptoms worsen or become uncontrollable.

Data sources and input parameters
---------------------------------

A series of Phase III randomized controlled trials investigating ulipristal acetate constitute the evidence base for UPA (PEARL I, II, III, and IV).[@b8-ceor-9-669],[@b17-ceor-9-669]--[@b19-ceor-9-669] The primary end points of these trials evaluated bleeding in terms of the pictorial bleeding assessment chart (PBAC). Secondary end points included comparative measures of pain and discomfort through the visual analog scale (VAS) and QOL through the Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire (PEARL II, III, and IV) and three-level, five-dimension EuroQoL instrument (EQ-5D, PEARL III and IV). PEARL I and II studied presurgical patients, while PEARL III and IV studied patients eligible for repeated intermittent use. PEARL IV was used as the primary source of data for UPA efficacy in this evaluation. The placebo arm of the PEARL I trial was the primary data source for BSC as patients were allowed to take both NSAIDs and iron.

UPA treatment break assumption
------------------------------

The UPA indication states that patients should receive 3 months of treatment followed by a minimum of 2 months off treatment before beginning the next treatment course. It was assumed that patients who did not withdraw after eight courses exhibited maintained symptom control beyond 2 months. In the model, patients adhere to a 3+2 treatment schedule for the first eight courses (\~38 months of therapy), after which patients have an average of a 6-month treatment break (ie, 3+6) in the following courses.

Effectiveness and patient progression
-------------------------------------

Treatment effectiveness is operationalized as bleeding and pain/discomfort while on treatment with UPA or iron+NSAID, estimated from trial data as reported in the "QOL" section. Patients treated with UPA withdraw to surgery and iron+NSAID at variable rates during courses 1--4 according to the PEARL IV trial data ([Table 1](#t1-ceor-9-669){ref-type="table"}). After course four, patients are assumed to withdraw at a rate proportional to iron+NSAID (described in [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D143557.pdf)). Patients treated with iron+NSAID were assumed to withdraw to surgery at a constant rate based on observational data.[@b20-ceor-9-669] The BSC withdrawal rate and UPA withdrawal following course 4 are described in [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D143557.pdf).

QOL
---

Patients' QOL was measured through the instrument EQ-5D, using UK-based QOL weights associated with each of the five health dimensions defined in the EQ-5D instrument.[@b25-ceor-9-669] While patients are on treatment with either UPA or iron+NSAID, EQ-5D QOL weights were established using a previously described function.[@b26-ceor-9-669] In each cycle, the equation adjusts the underlying age-dependent, population-based QOL by the average levels of bleeding and pain in that cycle. [Table 2](#t2-ceor-9-669){ref-type="table"} illustrates this relationship using a patient aged 42 years as an example.

In the surgery and postsurgery health states, age- dependent QOL weights of the general population in the UK were applied.[@b27-ceor-9-669]

Extrapolation of UPA and iron+NSAID efficacy data was necessary as the time horizon of the analysis extends beyond the available trial data. For patients remaining on treatment with iron+NSAID, the last observed bleeding and pain values were assumed to stay constant. For UPA, the PBAC and VAS levels in the last observed treatment course were assumed to repeat indefinitely. Further details of the extrapolations are included as [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D143557.pdf).

Patients undergoing surgery receive a QOL decrement from the procedure, differentiated by the type and approach of surgery.[@b28-ceor-9-669] QOL decrements relating to surgical events last for a total of 1 year, which are summarized in [Table 3](#t3-ceor-9-669){ref-type="table"}. The details of adverse event QOL decrements values are included as [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D143557.pdf).

Decrements to QOL were also applied for adverse events due to surgery, UPA treatment, and iron+NSAID treatment. The frequencies of adverse events were based on published trial data[@b8-ceor-9-669],[@b29-ceor-9-669],[@b30-ceor-9-669] and were assumed to last for 1 month. Short-term adverse events from surgery occur within 1 year of surgery. Persistent adverse events are also applied for hysterectomy patients, which are present 12 months after the intervention.

Costs
-----

In the base-case analysis, costs for UPA, iron+NSAID, surgery, adverse events, and patient follow-up were included ([Table 4](#t4-ceor-9-669){ref-type="table"}).

Analysis
--------

The estimated ICERs are compared to the cost-effectiveness thresholds of £20,000--30,000 currently employed by NICE in England.

The model's input parameters are subject to uncertainty, which was quantified through probabilistic sensitivity analysis (PSA). In this analysis, uncertainty (represented by probability distributions) in input parameters associated with sampling uncertainty was propagated through the model using simulation methods. Based on 10,000 simulations, the probability of UPA being cost-effective at different threshold values is assessed and reported. Distributional assumptions regarding input parameters are included as [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D143557.pdf).

Scenario analyses were also conducted by varying model inputs not associated with statistical uncertainty to investigate their impact on the cost-effectiveness results.

Results
=======

In the base-case analysis, the UPA strategy is associated with 6.696 QALYs and a cost of £6,669. The BSC strategy is associated with 6.610 QALYs and a cost of £5,555. Incrementally, UPA followed by surgery as needed is estimated to add 0.087 QALYs at a cost of £1,115, resulting in a cost per QALY gained of £12,850, compared with BSC.

A scenario analysis including costs of productivity loss[@b41-ceor-9-669] falling outside the health care budget was calculated, where patients treated with iron+NSAID were estimated to be off work for an additional 1.5 days per month compared with UPA, while those receiving abdominal surgery, laparoscopic or vaginal surgery, or uterine artery embolization spent 74, 56, and 7 days away from work, as a one-time event. Other scenarios varying withdrawal rates, duration of UPA treatment break, age of incident patients, and the age of menopause are reported in [Table 5](#t5-ceor-9-669){ref-type="table"}.

Further sensitivity analyses are presented in [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D143557.pdf).

PSA
---

The results of the PSA are presented graphically as a plot on the cost-effectiveness plane ([Figure 2](#f2-ceor-9-669){ref-type="fig"}).

For cost-effectiveness thresholds of £20,000 and £30,000, the probability of UPA strategy being cost-effective was \~85% and 96%, respectively. In order for UPA strategy to have a 50% (75%) \[95%\] probability of being cost-effective compared with BSC, the threshold must be at least £12,850 (£16,950) \[£27,800\]. The probability of cost-effectiveness at different threshold values was plotted as a cost-effectiveness acceptability curve ([Supplementary materials](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D143557.pdf)).

Discussion
==========

The base-case ICER of £12,850 per QALY gained is below the commonly accepted threshold of £20,000-30,000 in England for the NHS payer, implying that UPA followed by surgery as needed is cost-effective compared to BSC for patients wishing to avoid surgery. The QALY loss over the duration of the model in the scenario where UPA is not available is approximately equivalent to having pneumonia continuously for one year.[@b42-ceor-9-669] The results of the analysis presented in this paper expand the overall evaluation of UPA as a treatment for women with the prevalent condition of UF.

Probabilistic and scenario sensitivity analyses showed that the conclusion of cost-effectiveness holds in many cases. An analysis of particular note is the inclusion of productivity losses (sometimes called the societal perspective), where treating patients with the UPA strategy instead of the BSC strategy results in health gains and provides additional value to the wider economy. These values are not likely to impact the NHS budget directly and therefore the total cost to the NHS is still positive. Although it is not clear how to explicitly take these potential benefits into account in a constrained NHS perspective, the results indicate that there may be wider social benefits associated with UPA treatment. Furthermore, in some jurisdictions a societal perspective is advocated (eg, Sweden and Norway), and these gains would be considered in an economic evaluation of UPA.

There is a lack of robust data regarding certain key model parameters. For example, if patients remain on a 3+2 treatment schedule indefinitely in combination with conceivable changes in other parameters, scenarios can arise where the ICER is above the standard cost-effectiveness threshold range. Conversely, extending the break, or applying it earlier than the ninth treatment cycle, increases the strength of the cost-effective result. Second, patients receiving iron+NSAID may not be in regular contact with gynecological specialists, leading to uncertainty in the input parameters relating to this patient group. If these patients are treated less often than assumed in the analysis, the cost of this treatment arm will decrease.

In the analysis, there are more patients receiving surgery with the BSC strategy compared with the UPA strategy. Therefore, the model may be conservative as it excludes potential quality-of-life decrements that may be relevant to the patient population wishing to avoid surgery, such as feelings of lost femininity and anxiety before surgery.

Efficacy data for UPA were limited in time compared to the duration of the analysis, and trial-based follow-up was not as frequent as required to inform monthly disease progression parameters. Therefore, interpolation and extrapolation were necessary in order to model patients over the time horizon and are a source of uncertainty. This source of uncertainty is unavoidable in most health economic assessments, and sensitivity analyses show that the conclusion that UPA is cost-effective appears valid when investigating the importance of these parameters.

The results generally show that intermittent treatment with UPA followed by surgery as needed is cost-effective compared to BSC in patients wishing to avoid surgery. Future research should analyze the cost-effectiveness of UPA in alternative patient populations, health care perspectives, and compared to different interventions. In particular, the cost-effectiveness of using UPA as a replacement for surgery in perimenopausal patients should be studied, as UPA may allow these patients to reach menopause (at which time many experience natural symptom reduction), avoiding an invasive surgical procedure. From a clinical point of view, it would be beneficial to understand more about the impact of patients' preferences for avoiding surgery as well as the patient group treated with BSC in terms of demographics, QOL, and resource use.
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![Patient flow diagram.\
**Abbreviations:** NSAID, non-steroidal anti-inflammatory drug; UPA, ulipristal acetate 5 mg.](ceor-9-669Fig1){#f1-ceor-9-669}

![PSA iterations plotted on a cost-effectiveness plane.\
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###### 

Summary of withdrawals

  Risk of withdrawal (monthly)                             To iron+NSAID (%)                                                            To first surgery (%)
  -------------------------------------------------------- ---------------------------------------------------------------------------- --------------------------------------------------------------------------------------------
  From UPA (course 1)[@b8-ceor-9-669]                      0.2                                                                          1.2
  From UPA (course 2)[@b8-ceor-9-669]                      0.6                                                                          1.5
  From UPA (course 3)[@b8-ceor-9-669]                      0.5                                                                          0.9
  From UPA (course 4)[@b8-ceor-9-669]                      0.3                                                                          0.9
  From UPA (course 5+)[@b8-ceor-9-669],[@b20-ceor-9-669]   0.4                                                                          0.2
  From iron+NSAID[@b20-ceor-9-669]                         N/A                                                                          0.5
                                                                                                                                        
  **Procedures**                                           **Withdrawal to first surgery[@b21-ceor-9-669],[@b22-ceor-9-669]** **(%)**   **Distribution of resurgery[@b21-ceor-9-669],[@b23-ceor-9-669],[@b24-ceor-9-669]** **(%)**
                                                                                                                                        
  Abdominal hysterectomy                                   46.4                                                                         53.3
  Laparoscopic hysterectomy                                6.4                                                                          7.3
  Vaginal hysterectomy                                     8.5                                                                          9.8
  Abdominal myomectomy                                     8.5                                                                          0.0
  Laparoscopic myomectomy                                  8.2                                                                          0.0
  Vaginal myomectomy                                       17.2                                                                         0.0
  Uterine artery embolization                              4.8                                                                          29.6

**Abbreviations:** NSAID, non-steroidal anti-inflammatory drug; UPA, ulipristal acetate 5 mg.

###### 

Sample quality of life (EQ-5D) weights given bleeding (PBAC) and pain (VAS) values

  Bleeding level (PBAC)   Pain level (VAS)   Resulting quality of life (EQ-5D)[@b26-ceor-9-669]
  ----------------------- ------------------ ----------------------------------------------------
  75                      0                  0.874
  100                     10                 0.828
  250                     20                 0.770
  500                     25                 0.719

**Note:** Average EQ-5D value for the UK population of age 42 years is equal to 0.883.[@b27-ceor-9-669] Copyright © 2015. Elsevier. Reproduced from Geale K, Hultberg M, Henriksson M. Applying symptom-based utility functions in health economic modelling: a case study of uterine fibroids. *Value Health*. 2015;18(7):A728.[@b26-ceor-9-669]

**Abbreviations:** EQ-5D, three-level, five-dimension EuroQoL instrument; PBAC, pictorial bleeding assessment chart; VAS, visual analog scale.

###### 

Summary of QOL and corresponding decrements

  General population[@b27-ceor-9-669]         EQ-5D QOL weight                Comment
  ------------------------------------------- ------------------------------- -------------------------------------------------------------------------------------------------------------
  Age 41--45 years                            0.883                           Starting age of patients equal to 41.5 years
  Age 46--50 years                            0.865                           
  Age 51--55 years                            0.836                           Age at menopause equal to 51.4
                                                                              
  **Surgery**[@b28-ceor-9-669]                **EQ-5D QOL decrement/month**   **Comment**
                                                                              
  Abdominal approach                          −0.07                           
  Laparoscopic approach                       −0.04                           
  Vaginal approach                            −0.02                           
  UAE                                         −0.02                           Assumed equal to the vaginal approach
                                                                              
  **Surgery anticipation**[@b31-ceor-9-669]   **EQ-5D QOL decrement/month**   **Comment**
                                                                              
  Waiting for surgery                         −0.01                           2 months from referral to completed surgery
                                                                              
  **Adverse events**                          **EQ-5D QOL decrement/month**   **Comment**
                                                                              
  Short-term (all treatments)                 0.000 to −0.017                 Details in [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D143557.pdf)
  Persistent (hysterectomy)                   −0.001 to −0.130                Details in [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D143557.pdf)

**Abbreviations:** EQ-5D, three-level, five-dimension EuroQoL instrument; QOL, quality of life; UAE, uterine artery embolization.

###### 

Summary of costs

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Treatments                                                                                    Annual cost (£)       Note
  --------------------------------------------------------------------------------------------- --------------------- ---------------------------------------------------------------------
  UPA (3+2 months)[@b32-ceor-9-669]                                                             873                   Includes direct cost of UPA (£821.74) plus the cost of iron+NSAID

  Iron+NSAID[@b32-ceor-9-669],[@b33-ceor-9-669]                                                 52                    NSAIDs: 10% of patients take seven 200 mg tablets/day\
                                                                                                                      Iron: 8.8% of patients take two 200 mg tablets/day[@b34-ceor-9-669]

  Hysterectomy[a](#tfn5-ceor-9-669){ref-type="table-fn"},[@b35-ceor-9-669]--[@b37-ceor-9-669]   3,083                 Surgery plus endometrial biopsy and hysteroscopy

  Myomectomy[a](#tfn5-ceor-9-669){ref-type="table-fn"},[@b35-ceor-9-669]--[@b37-ceor-9-669]     2,965                 Surgery plus endometrial biopsy and hysteroscopy

  Uterine artery embolization[@b37-ceor-9-669]                                                  2,093                 Procedure cost plus endometrial biopsy and hysteroscopy

                                                                                                                      

  **Monitoring**                                                                                **Annual cost (£)**   **Usage**

                                                                                                                      

  Gynecologist consultation[@b38-ceor-9-669]                                                    51                    One per year (UPA and iron+NSAID)

  GP visit[@b38-ceor-9-669]                                                                     198                   Two 30-minute consultations per year (iron+NSAID only)

  Ultrasound[@b37-ceor-9-669]                                                                   160                   One per year (UPA and iron+NSAID)

                                                                                                                      

  **Postsurgery follow-up**                                                                                           

                                                                                                                      

  Gynecologist consultation[@b38-ceor-9-669]                                                    51                    Regular check-up

                                                                                                                      

  **Adverse events**[b](#tfn6-ceor-9-669){ref-type="table-fn"}                                  **Annual cost (£)**   **Note**

                                                                                                                      

  UPA[@b13-ceor-9-669],[@b32-ceor-9-669],[@b37-ceor-9-669],[@b38-ceor-9-669]                    90                    Adverse event frequency sourced from PEARL IV trial data

  Iron+NSAID[@b18-ceor-9-669],[@b37-ceor-9-669]                                                 152                   Adverse event frequency sourced from PEARL I trial data

  Hysterectomy (short term)[@b29-ceor-9-669],[@b37-ceor-9-669]                                  607                   Complications lasting 1 month

  Hysterectomy (persistent)[@b37-ceor-9-669]--[@b39-ceor-9-669]                                 81                    Complications lasting 1 year (in addition to short-term)

  Myomectomy[@b30-ceor-9-669],[@b37-ceor-9-669],[@b38-ceor-9-669]                               1,180                 

  Uterine artery embolization[@b30-ceor-9-669],[@b32-ceor-9-669],[@b37-ceor-9-669]              760                   

                                                                                                                      

  **Productivity loss**                                                                         **Daily cost (£)**    **Note**

                                                                                                                      

  One day off work[@b40-ceor-9-669]                                                             118                   Equivalent to average daily salary (human capital approach)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

On average over the abdominal, laparoscopic, and vaginal approaches.

Details of adverse event costs are included as [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php?f=143557.pdf).

**Abbreviations:** GP, general practitioner; NSAID, non-steroidal anti-inflammatory drug; UPA, ulipristal acetate 5 mg.

###### 

Scenario analyses

  Scenarios                                                                     Incremental costs (£)   Incremental QALYS   ICER (£/QALYs gained)
  ----------------------------------------------------------------------------- ----------------------- ------------------- -----------------------
  Inclusion of cost of productivity loss                                        --10,725                0.087               UPA dominates BSC
  Withdrawal rate from iron+NSAID to first surgery +25%                         1,077                   0.061               17,611
  Withdrawal rate from iron+NSAID to first surgery −25%                         1,167                   0.113               10,301
  No withdrawals after UPA course 4                                             1,151                   0.070               16,509
  2-month breaks for all UPA courses                                            2,226                   0.090               24,821
  2-month breaks for all UPA courses (inclusion of cost of productivity loss)   --9,614                 0.090               UPA dominates BSC
  Starting age 43.5 years                                                       1,111                   0.081               13,775
  Starting age 39.5 years                                                       1,126                   0.086               13,044
  Age of menopause 53.4 years                                                   1,126                   0.086               13,054
  Age of menopause 49.4 years                                                   1,111                   0.081               13,764

**Abbreviations:** BSC, best supportive care; ICER, incremental cost-effectiveness ratio; NSAID, non-steroidal anti-inflammatory drug, QALY, quality-adjusted life-year; UPA, ulipristal acetate 5 mg.
